Thiogenesis Announces Commencement of OTCQX Trading in the U.S.
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF) has announced its common shares are now trading on the OTCQX Best Market under the symbol TTIPF. This represents a significant milestone as OTCQX is the highest-level market of OTC Markets, hosting 12,000 U.S. and global securities.
The company has also secured DTC eligibility status, enabling electronic settlement of shares across the United States and 131 other countries. Thiogenesis will maintain its listing on the TSX Venture Exchange under TTI.
Additionally, the company recently received final regulatory clearance to initiate a Phase 2 clinical trial in Europe for the treatment of Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes (MELAS). The trial's commencement is pending completion of administrative procedures and material provision to trial sites.
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF) ha annunciato che le sue azioni ordinarie sono ora negoziate sul OTCQX Best Market con il simbolo TTIPF. Questo rappresenta un traguardo significativo poiché OTCQX è il mercato di livello più alto di OTC Markets, ospitando 12.000 titoli statunitensi e globali.
La società ha inoltre ottenuto lo status di idoneità DTC, che consente la liquidazione elettronica delle azioni negli Stati Uniti e in altri 131 paesi. Thiogenesis manterrà la sua quotazione sulla TSX Venture Exchange sotto TTI.
In aggiunta, la società ha recentemente ricevuto l'approvazione finale da parte delle autorità per avviare un trial clinico di Fase 2 in Europa per il trattamento dell'Encefalomiopatia Mitocondriale con Acidosi Lattica ed episodi simili all'ictus (MELAS). L'inizio del trial è in attesa del completamento delle procedure amministrative e della fornitura di materiale ai siti di prova.
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF) ha anunciado que sus acciones comunes ahora se están negociando en el OTCQX Best Market bajo el símbolo TTIPF. Esto representa un hito significativo, ya que OTCQX es el mercado de más alto nivel de OTC Markets, que alberga 12,000 valores estadounidenses y globales.
La compañía también ha obtenido el estatus de elegibilidad DTC, lo que permite la liquidación electrónica de acciones en los Estados Unidos y en 131 otros países. Thiogenesis mantendrá su cotización en la TSX Venture Exchange bajo TTI.
Además, la compañía recibió recientemente la aprobación regulatoria final para iniciar un ensayo clínico de Fase 2 en Europa para el tratamiento de la Encefalomiopatía Mitocondrial con Acidosis Láctica y episodios similares a un accidente cerebrovascular (MELAS). El inicio del ensayo está pendiente de la finalización de los procedimientos administrativos y la provisión de material a los sitios de ensayo.
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF)는 자사의 보통주가 이제 OTCQX Best Market에서 TTIPF라는 기호로 거래되고 있다고 발표했습니다. 이는 OTCQX가 OTC Markets의 최고 수준의 시장으로, 12,000개의 미국 및 글로벌 증권을 보유하고 있어 중요한 이정표를 나타냅니다.
회사는 또한 DTC 적격 상태를 확보하여 미국 및 131개국에서의 전자 정산을 가능하게 했습니다. Thiogenesis는 TTI 기호로 TSX 벤처 거래소에 상장된 상태를 유지할 것입니다.
또한, 회사는 최근에 유럽에서 유산산성 뇌병증 및 뇌졸중 유사 증상(MELAS) 치료를 위한 2상 임상 시험을 시작하기 위한 최종 규제 승인을 받았습니다. 시험 시작은 행정 절차 완료 및 시험 사이트에 대한 자료 제공을 기다리고 있습니다.
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF) a annoncé que ses actions ordinaires sont désormais négociées sur le OTCQX Best Market sous le symbole TTIPF. Cela représente une étape importante car OTCQX est le marché de niveau le plus élevé des marchés OTC, accueillant 12 000 titres américains et mondiaux.
L'entreprise a également obtenu le statut d'éligibilité DTC, permettant le règlement électronique des actions aux États-Unis et dans 131 autres pays. Thiogenesis maintiendra son inscription à la TSX Venture Exchange sous TTI.
De plus, l'entreprise a récemment reçu l'approbation réglementaire finale pour initier un essai clinique de phase 2 en Europe pour le traitement de l'Encéphalomyopathie Mitochondriale avec Acido-Lactique et épisodes similaires à un AVC (MELAS). Le début de l'essai est en attente de l'achèvement des procédures administratives et de la fourniture de matériel aux sites d'essai.
Thiogenesis Therapeutics (TSXV: TTI) (OTCQX: TTIPF) hat bekannt gegeben, dass ihre Stammaktien nun unter dem Symbol TTIPF auf dem OTCQX Best Market gehandelt werden. Dies stellt einen bedeutenden Meilenstein dar, da OTCQX der höchste Markt von OTC Markets ist und 12.000 US-amerikanische und globale Wertpapiere beherbergt.
Das Unternehmen hat außerdem den DTC-Status erhalten, der die elektronische Abwicklung von Aktien in den Vereinigten Staaten und in 131 anderen Ländern ermöglicht. Thiogenesis wird seine Notierung an der TSX Venture Exchange unter TTI beibehalten.
Darüber hinaus hat das Unternehmen kürzlich die endgültige regulatorische Genehmigung erhalten, um eine Phase-2-Studie in Europa zur Behandlung der mitochondrialen Enzephalomyopathie mit Laktatazidose und schlagähnlichen Episoden (MELAS) zu starten. Der Beginn der Studie steht noch aus, da die administrativen Verfahren und die Materialbereitstellung für die Prüfstandorte abgeschlossen werden müssen.
- Uplisting to OTCQX Best Market, increasing U.S. investor accessibility
- Obtained DTC eligibility, enabling broader electronic trading access
- Received regulatory clearance for Phase 2 MELAS clinical trial in Europe
- None.
San Diego, California--(Newsfile Corp. - February 12, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that its common shares are now trading on the OTCQX Best Market under the ticker symbol TTIPF. The OTCQX Best Market is the highest-level market of OTC Markets on which 12,000 U.S. and global securities trade. Trading on OTCQX will enhance the visibility and accessibility of the Company to U.S. investors. Thiogenesis' common shares will continue to trade on the TSX Venture Exchange under the symbol TTI.
Thiogenesis previously announced that it has attained Depository Trust Company ("DTC") eligibility status in the U.S. DTC eligibility allows electronic settlement of the Company's common shares and manages electronic clearing and settlement of publicly traded companies across the United States and in 131 other countries. U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com/stock/TTIPF/quote.
On January 27, 2025, Thiogenesis announced that it has received final regulatory clearance required to initiate a Phase 2 clinical trial, in Europe, for the treatment of Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes ("MELAS"). The Company anticipates initiating the Phase 2 clinical trial in MELAS, subject to the completion of supporting administrative procedures and the provision of materials to the trial sites.
About MELAS
Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes ("MELAS") is a rare, inherited mitochondrial disorder, most often caused by a mutation of m.3243A>G in the MT-TL1 gene in mitochondrial DNA. Initial symptoms usually include seizures, vomiting, headaches, muscle weakness, loss of appetite and fatigue. Longer term the disease may cause a loss of motor skills and intellectual disability. MELAS usually presents itself before the age of 20. Oxidative stress and taurine deficiency play an important role in mitochondria and are potential pathological mechanisms of mitochondrial disorders, making for viable targets for the treatment of MELAS and other mitochondrial diseases. MELAS is an orphan disease for which there are no approved drugs.
About Thiogenesis
Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) is a clinical-stage biopharmaceutical company operating through its wholly owned subsidiary based in San Diego, CA. Thiogenesis is developing sulfur-containing prodrugs that act as precursors to previously approved thiol compounds, with the potential to treat serious pediatric diseases with unmet medical needs. Prodrugs are drugs that contain previously approved active ingredients and are modified so that they only become active when metabolized. For regulatory purposes prodrugs can use existing third-party safety data in regulatory submissions in the streamlined 505 (b)(2) regulatory pathway in the US, and its equivalent hybrid system in Europe, to proceed into human efficacy trials with regulatory approval. Prodrugs may enhance the profile of the active ingredient to increase its bioavailability and reduce side effects. The Company's initial target indications include Mitochondrial Encephalopathy Lactic Acidosis and Stroke ("MELAS"), Leigh's syndrome, Rett syndrome and pediatric MASH.
For further information, please contact:
Brook Riggins, Director, and CFO
Email: info@thiogenesis.com
Tel.: (888) 223-9165
Forward Looking Statements
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward- looking statements") within the meaning of Canadian and U.S. securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions, or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange, nor the OTC Markets Group Inc. (OTCQX: OTCM) accepts responsibility for the adequacy or accuracy of this news release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/240489
FAQ
What does Thiogenesis' (TTIPF) uplisting to OTCQX Best Market mean for investors?
When did Thiogenesis (TTIPF) receive clearance for its Phase 2 MELAS trial?
What is the significance of Thiogenesis (TTIPF) obtaining DTC eligibility?
Where can investors find real-time quotes for Thiogenesis stock (TTIPF)?
